Bevacizumab, a recombinant humanized monoclonal antibody to VEGF and known by its brand name, Avastin®, blocks tumor cell-derived VEGF-A, impairing the development of new vessels and leading to tumor starvation and, consequently, growth inhibition (19). This evidence concerns the gene VEGFA and neoplasm.